Insmed Incorporated — Q1 2014 Form 10-Q
Reporting period: Three months ended March 31, 2014. Insmed is a development-stage biopharmaceutical company focused on inhaled therapies; ARIKAYCE was its lead product candidate. The company reported no revenue.
Financial highlights
| Metric | Q1 2014 | Q1 2013 / comparison |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $11.4 million | $10.3 million; up 9.8% |
| General and administrative expense | $6.7 million | $4.0 million; up $2.7 million |
| Operating loss | $18.1 million | $14.3 million |
| Net loss | $14.3 million; $0.36 per share | $13.7 million; $0.43 per share |
| Operating cash used | $12.6 million | $11.2 million |
| Cash and cash equivalents | $101.3 million at March 31, 2014 | $113.9 million at December 31, 2013 |
| Working capital | $86.2 million | — |
Amounts are in U.S. dollars. The $4.4 million Q1 2014 tax benefit and cash receipt came from selling New Jersey tax-loss carryforwards; excluding this cash receipt, operating cash use was $17.0 million. The comparable 2013 figures were a $1.2 million benefit and $12.4 million operating cash use excluding that receipt. The tax benefit reduced the reported net loss.
Total assets were $166.6 million and total liabilities $34.9 million at March 31, 2014. Debt had $20.0 million principal outstanding, bearing 9.25% interest; $5.2 million was classified as current and $14.6 million as long-term, net of debt discounts and charges. Principal payments were scheduled to begin July 1, 2014; a further interest-only extension through December 2014 was conditional on a $100,000 fee and positive NTM trial data. The notes mature January 1, 2016.
Material changes and business developments
- Net loss increased $0.6 million year over year despite the larger tax benefit. R&D rose $1.0 million, mainly from compensation, stock-based compensation and manufacturing costs, partly offset by lower clinical trial expense after completion of the CF Phase 3 study. G&A increased $2.7 million, including higher pre-commercial, personnel and stock-based compensation costs.
- Cash declined $12.6 million during the quarter. The company reported $0.3 million in investing cash outflows and $0.3 million in financing inflows, principally option exercises.
- In the Phase 2 NTM trial, ARIKAYCE did not meet the prespecified primary endpoint (p=0.148), but achieved statistical significance on the key secondary culture-conversion endpoint: 11 of 44 treated patients versus 3 of 45 placebo patients had negative cultures at day 84 (p=0.01). Additional analyses were ongoing.
- For CF patients with Pseudomonas, the completed European and Canadian Phase 3 study met its primary non-inferiority endpoint versus twice-daily TOBI. A two-year open-label extension was ongoing.
- Insmed entered a February 2014 contract manufacturing agreement with Therapure to prepare larger-scale ARIKAYCE production. The company expected to pay approximately $12 million for facility build-out and related manufacturing costs. Its existing Althea manufacturing arrangement was due to expire in July 2014, and an extension was under negotiation.
Outlook, risks and contingencies
- Management said current funds were sufficient for the next 12 months, but stated that additional capital could be needed and might not be available on favorable terms, or at all. The company expected no material revenue for at least the next few years and could require financing sooner if development or commercialization costs increase.
- For Q2 2014, management estimated operating cash requirements of $18–20 million and capital expenditures of $3–5 million for the Bridgewater headquarters build-out. For 2014, priorities included further ARIKAYCE development, manufacturing capacity, regulatory work and launch preparation.
- Management expected to start an additional NTM study in the second half of 2014 and planned regulatory filings for the CF indication in Europe and Canada in the second half of 2014. The NTM regulatory pathway remained subject to discussions with the FDA and EMA; a further NTM study was expected.
- Key risks include clinical and regulatory uncertainty, the NTM primary-endpoint miss, manufacturing capacity and quality, and dependence on ARIKAYCE. The FDA had previously cited lung tumors in 2 of 120 rats at the highest dose in a two-year inhalation study; relevance to humans was unknown. The company reported no evidence of neoplasia in its completed dog inhalation toxicity studies.
- The Delaware appraisal action concerning former Transave shareholders settled before the scheduled April 2014 trial; settlement terms were still being negotiated. Insmed expected indemnification for settlement and defense costs and retained 1,765,271 holdback shares as security.
- A named executive officer was transitioning to a special-advisor role and expected to leave later in 2014; Insmed anticipated one-time transition and separation costs beginning in Q2.
Important facts for investors to verify
- Whether follow-up NTM analyses, FDA/EMA discussions and additional trials establish a viable development and approval path after the primary endpoint was missed.
- Whether expected CF regulatory submissions and the NTM study proceed on schedule, and whether regulators require additional evidence.
- Cash burn against management’s 12-month funding assessment, planned Q2 cash needs and headquarters capital spending; assess whether further financing may be required.
- Progress extending Althea supply, Therapure facility construction and validation, and readiness to supply clinical trials or commercial launch.
- Final settlement terms and indemnification in the Transave appraisal action, and the amount and timing of executive transition costs.